I'll keep an eye out for that J & J priority application. If, they get it, I think the time frame for approval is about 6 months, Oct 2019 instead of Jan 2020.
There are a lot of SGLT2 drugs under development. Zynquista was recently approved by the EU but not the FDA for Type 1 diabetes. Our CEO, Dr Lipscombe implies that PromarkerD may be used each time any of these new drugs are prescribed. That, is a huge statement! The future looks very good for PIQ.
Ann: Appendix 4C - March 2019 Quarterly Report, page-37
-
- There are more pages in this discussion • 18 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add PIQ (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
73.0¢ |
Change
-0.030(3.95%) |
Mkt cap ! $95.63M | |||
| Open | High | Low | Value | Volume |
| 75.0¢ | 75.0¢ | 73.0¢ | $232.0K | 311.4K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 21156 | 73.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 74.0¢ | 1352 | 1 |
View Market Depth
| Last trade - 16.10pm 16/10/2024 (20 minute delay) ? |
| PIQ (ASX) Chart |